Document:

Exhibit 10.12

 

AMENDMENT NO. 1 TO

CONSULTANT AGREEMENT

 

THIS AMENDMENT NO. 1 TO CONSULTANT
AGREEMENT (this “Amendment”), dated as of October ___, 2021, by and among MAINZ BIOMED B.V. (including upon conversion to
a Naamloze Venootschap under Dutch law, the “Company”) and William Caragol (the “Consultant”).

 

WHEREAS, the Company and Consultant
are parties to that certain Consultant Agreement, dated as of July 16, 2021 (the “Consultant Agreement”);

 

WHEREAS, pursuant to Section
19 of the Consultant Agreement, the parties desire to amend the Consultant Agreement as provided in this Amendment; and

 

NOW, THEREFORE, in consideration
of the foregoing and the mutual agreements contained in this Amendment, and for other good and valuable consideration, the receipt and
sufficient of which are hereby acknowledged, intending to be legally bound, the parties hereto agree as follows:

 

1. Schedule 4.2 to the Consultant Agreement is
hereby amended and replaced in its entirety by the following:

 

“After a Stock Option Plan has been
approved by the Board of Directors and shareholders of the Company \but prior to the IPO, the Company and Consultant shall enter into
the Stock Option Agreement attached here to as Exhibit A. Consultant’s equity ownership will be reviewed within 12 months of the
IPO for increase, if applicable, to be consistent with industry standards for CFOs of similarly situated companies.”

  

2. Except as expressly amended and modified by
this Amendment, the terms, representations, warranties, covenants and other provisions of the Consultant Agreement are and shall continue
to be in full force and effect in accordance with the Consultant Agreement.

 

3. This Amendment may be executed in counterparts,
each of which shall constitute an original, but all of which shall constitute one agreement. This Amendment shall become effective upon
delivery to each party of an executed counterpart or the earlier delivery to each party of original, photocopied, or electronically transmitted
signature pages that together (but need not individually) bear the signatures of all other parties.

 

4. This Amendment is limited by its terms and
does not and shall not serve to amend or waive any provision of the Consultant Agreement except as expressly provided for in this Amendment.
All references in the Amendment to “this Consultant Agreement” or terms such as “herein”, “hereof”
or similar terms shall mean the Consultant Agreement as amended by this Amendment. Capitalized terms used but not defined herein shall
have the meanings ascribed to such terms in the Consultant Agreement.

 

5. The provisions of Section 16 (Governing Law;
Jurisdiction and Venue) of the Consultant Agreement shall apply to this Amendment as if written out below.

 

[Signature Page to follow]

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Amendment to be signed, all as of the date first written above.

 

	WILLIAM CARAGOL	 	MAINZ BIOMED B.V.
		 	 
		 	 
	William Caragol	 	Name:
		 	Title:
		 	 
		 	 
		 	Name:
		 	Title:Exhibit 10.13

 

AMENDMENT NO. 1 TO

MANAGEMENT SERVICES AGREEMENT

 

THIS AMENDMENT NO. 1 TO MANAGEMENT
SERVICES AGREEMENT (this “Amendment”), dated as of October ___, 2021, by and among MAINZ BIOMED B.V. (including upon conversion
to a Naamloze Venootschap under Dutch law, the “Company”) and Dr. Moritz Eidens (“Eidens”).

 

WHEREAS, the Company and Eidens
are parties to that certain Management Services Agreement, dated as of September 13, 2021 (the “Management Services Agreement”);

 

NOW, THEREFORE, in consideration
of the foregoing and the mutual agreements contained in this Amendment, and for other good and valuable consideration, the receipt and
sufficient of which are hereby acknowledged, intending to be legally bound, the parties hereto agree as follows:

 

1. Section 4 (2)of the Management Services Agreement
is hereby amended and replaced in its entirety by the following:

 

“After a Stock Option Plan has been approved
by the Board of Directors and shareholders of the Company but prior to the IPO, the Company and Eidens shall enter into the Stock Option
Agreement attached here to as Exhibit A. Eidens’ equity ownership will be reviewed within 12 months of the IPO for increase, if
applicable, to be consistent with industry standards for CSOs of similarly situated companies.”  

 

2. Except as expressly amended and modified by
this Amendment, the terms, representations, warranties, covenants and other provisions of the Management Services Agreement are and shall
continue to be in full force and effect in accordance with the Management Services Agreement.

 

3. This Amendment may be executed in counterparts,
each of which shall constitute an original, but all of which shall constitute one agreement. This Amendment shall become effective upon
delivery to each party of an executed counterpart or the earlier delivery to each party of original, photocopied, or electronically transmitted
signature pages that together (but need not individually) bear the signatures of all other parties.

 

4. This Amendment is limited by its terms and
does not and shall not serve to amend or waive any provision of the Management Services Agreement except as expressly provided for in
this Amendment. All references in the Amendment to “this Management Services Agreement” or terms such as “herein”,
“hereof” or similar terms shall mean the Management Services Agreement as amended by this Amendment. Capitalized terms used
but not defined herein shall have the meanings ascribed to such terms in the Management Services Agreement.

 

5. The final provisions of Section 15 of the Management
Services Agreement shall apply to this Amendment as if written out below.

 

6. The Company shall continue the contract concluded
in Eidens’ favor for a retirement pension with Frankfurter Leben Gruppe, insurance policy no. PB-1747579367, formerly pro bAV (insurance
policy no. 000001256029), for an unlimited period of time and shall bear the premium payments. Furthermore, the Company shall continue
the contract concluded in Eidens’ favor for a retirement pension with AXA Lebensversicherung, insurance policy no. 46953515001,
for an unlimited period of time and shall bear the premium payments. An increase of pension benefits requires the consent of the shareholders.
This does not affect the dynamic nature of the respective contract.

 

To compensate these changes, Section 2 of the
Supplementary Agreement to the Managing Director Service Contract dated September 13, 2021 be void, as such agreed conditions will now
be borne by Mainz Biomed B.V instead of PharmGenomics GmbH.

 

[Signature Page to follow]

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment
to be signed, all as of the date first written above.

 

	DR. MORITZ EIDENS	 	MAINZ BIOMED B.V.
		 	 
	 	 	 
	Dr. Moritz Eidens	 	Name:
	 	 	Title:
	 	 	 
	 	 	 
	 	 	Name:
	 	 	Title:Exhibit
10.14

 

AMENDMENT
NO. 1 TO

MANAGEMENT
SERVICES AGREEMENT

 

THIS
AMENDMENT NO. 1 TO MANAGEMENT SERVICES AGREEMENT (this “Amendment”), dated as of October ___, 2021, by and among MAINZ BIOMED
B.V. (including upon conversion to a Naamloze Venootschap under Dutch law, the “Company”) and Philipp Freese (“Freese”).

 

WHEREAS,
the Company and Freese are parties to that certain Management Services Agreement, dated as of September 13, 2021 (the “Management
Services Agreement”);

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual agreements contained in this Amendment, and for other good and valuable consideration,
the receipt and sufficient of which are hereby acknowledged, intending to be legally bound, the parties hereto agree as follows:

 

1.
Section 4 (2)of the Management Services Agreement is hereby amended and replaced in its entirety by the following:

 

“After
a Stock Option Plan has been approved by the Board of Directors and shareholders of the Company but prior to the IPO, the Company and
Freese shall enter into the Stock Option Agreement attached here to as Exhibit A. Freese’s equity ownership will be reviewed within
12 months of the IPO for increase, if applicable, to be consistent with industry standards for COOs of similarly situated companies.”

  

2.
Except as expressly amended and modified by this Amendment, the terms, representations, warranties, covenants and other provisions of
the Management Services Agreement are and shall continue to be in full force and effect in accordance with the Management Services Agreement.

 

3.
This Amendment may be executed in counterparts, each of which shall constitute an original, but all of which shall constitute one agreement.
This Amendment shall become effective upon delivery to each party of an executed counterpart or the earlier delivery to each party of
original, photocopied, or electronically transmitted signature pages that together (but need not individually) bear the signatures of
all other parties.

 

4.
This Amendment is limited by its terms and does not and shall not serve to amend or waive any provision of the Management Services Agreement
except as expressly provided for in this Amendment. All references in the Amendment to “this Management Services Agreement”
or terms such as “herein”, “hereof” or similar terms shall mean the Management Services Agreement as amended
by this Amendment. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Management Services
Agreement.

 

5.
The final provisions of Section 15 of the Management Services Agreement shall apply to this Amendment as if written out below.

 

6.
The Company shall continue the direct insurance policies concluded in Freeses’s favor with Allianz, insurance policy numbers 5/570651/166
and 5/570651/170, for an unlimited period of time and shall bear the premium payments. Furthermore, the Company shall continue the contract
concluded in Freese’s favor for a retirement pension with Standard Life Versicherung, insurance policy no. 7299963, for an unlimited
period of time and shall bear the premium payments. An increase of pension benefits requires the consent of the shareholders. This does
not affect the dynamic nature of the respective contract.

 

To
compensate for that, Section 3 of the Supplementary Agreement to the Managing Director Service Contract dated September 13, 2021 will
be void, as such agreed conditions will now be borne by Mainz Biomed B.V instead of PharmGenomics GmbH-.

 

[Signature
Page to follow]

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be signed, all as of the date first written above.

 

	PHILIPP FREESE	 	MAINZ BIOMED B.V.
		 	 
	 	 	 
	Philipp Freese	 	Name:
	 	 	Title:
	 	 	 
	 	 	 
	 	 	Name:
	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]